<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Protara Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/protara-therapeutics-inc</link>
    <description>Latest news and press releases for Protara Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/protara-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c6b278dffbe2df11b271.webp</url>
      <title>Protara Therapeutics Inc</title>
      <link>https://6ix.com/company/protara-therapeutics-inc</link>
    </image>
    <item>
      <title>Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-american-urological-association-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-american-urological-association-annual-meeting</guid>
      <pubDate>Mon, 27 Apr 2026 20:05:00 GMT</pubDate>
      <description>NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial evaluating TARA-002 in patients with BCG-Naïve non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming American Urological Association (AU</description>
    </item>
    <item>
      <title>Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in</description>
    </item>
    <item>
      <title>TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/tara-002-demonstrates-68percent-complete-response-rate-at-six-months-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/tara-002-demonstrates-68percent-complete-response-rate-at-six-months-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the</description>
    </item>
    <item>
      <title>Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-inc-reports-inducement-210500469</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-inc-reports-inducement-210500469</guid>
      <pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
      <description>NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara’s Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to on</description>
    </item>
    <item>
      <title>Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-present-updated-interim-130000744</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-present-updated-interim-130000744</guid>
      <pubDate>Thu, 22 Jan 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 will be featured at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking</description>
    </item>
    <item>
      <title>Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-highlights-recent-updates-120000628</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-highlights-recent-updates-120000628</guid>
      <pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
      <description>On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026 Recently completed approximately $86 million public offering extending</description>
    </item>
    <item>
      <title>Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-dosing-first-130000873</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-dosing-first-130000873</guid>
      <pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now underway in its Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous (IV) Choline Chloride in patients receiving long-term parenteral support (PS). IV Choline Chloride, the Company’s investigational phospholipid substrate replacement therapy, wa</description>
    </item>
    <item>
      <title>Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-present-44th-annual-130000194</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-present-44th-annual-130000194</guid>
      <pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protar</description>
    </item>
    <item>
      <title>Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-receives-both-fda-130000230</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-receives-both-fda-130000230</guid>
      <pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
      <description>TARA-002 selected for FDA manufacturing development and readiness pilot programNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations for TARA-002, the Company’s investigational cell-based therapy, for the treatment of pediatric</description>
    </item>
    <item>
      <title>Protara Announces Closing of $75 Million Public Offering</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-announces-closing-75-million-210500317</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-announces-closing-75-million-210500317</guid>
      <pubDate>Mon, 08 Dec 2025 21:05:00 GMT</pubDate>
      <description>NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,043,479 shares of its common stock at a public offering price of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the pub</description>
    </item>
    <item>
      <title>Protara Announces Pricing of $75 Million Public Offering</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-announces-pricing-75-million-030300436</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-announces-pricing-75-million-030300436</guid>
      <pubDate>Fri, 05 Dec 2025 03:03:00 GMT</pubDate>
      <description>NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the publi</description>
    </item>
    <item>
      <title>Protara Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-announces-proposed-public-offering-211500949</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-announces-proposed-public-offering-211500949</guid>
      <pubDate>Thu, 04 Dec 2025 21:15:00 GMT</pubDate>
      <description>NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funde</description>
    </item>
    <item>
      <title>Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-updated-interim-130000153</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-updated-interim-130000153</guid>
      <pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
      <description>TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report in</description>
    </item>
    <item>
      <title>Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-host-conference-call-211500945</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-host-conference-call-211500945</guid>
      <pubDate>Mon, 01 Dec 2025 21:15:00 GMT</pubDate>
      <description>NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data wil</description>
    </item>
    <item>
      <title>Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-positive-interim-130000182</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-positive-interim-130000182</guid>
      <pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
      <description>80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasd</description>
    </item>
    <item>
      <title>Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-host-conference-call-213000603</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-host-conference-call-213000603</guid>
      <pubDate>Tue, 18 Nov 2025 21:30:00 GMT</pubDate>
      <description>NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 19, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label STARBORN-1 trial assessing TARA-002, the Company’s investigational cell-based therapy, in pediatric patients with</description>
    </item>
    <item>
      <title>Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-present-interim-data-130000958</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-present-interim-data-130000958</guid>
      <pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
      <description>NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) takin</description>
    </item>
    <item>
      <title>Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-third-quarter-130000188</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-announces-third-quarter-130000188</guid>
      <pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
      <description>Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to present interim analysis from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing ADVANCED-2 trial in 1Q 2026Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support now expected by year-end 2025Cash, cash equivalents and investments of approximately $134 milli</description>
    </item>
    <item>
      <title>Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-named-2026-best-210500360</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-named-2026-best-210500360</guid>
      <pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
      <description>NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has been named a BioSpace 2026 Best Place to Work. “Protara is thrilled to be recognized as one of the most sought-after biotech employers in the life sciences community,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “Our colleagues are crucial to every</description>
    </item>
    <item>
      <title>Protara Therapeutics to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-participate-upcoming-investor-120000819</link>
      <guid isPermaLink="true">https://6ix.com/company/protara-therapeutics-inc/news/protara-therapeutics-participate-upcoming-investor-120000819</guid>
      <pubDate>Wed, 27 Aug 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference. A fireside chat will take place on Thursday, September 4, 2025 at 1:35 pm ET in New York.H.C. Wainwright 27th Annual Global Investment Conference. A corporate presentation will tak</description>
    </item>
  </channel>
</rss>